|
|
 |
|
Viewing report
|
|
|
|
The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
GBI Research, Dec 2009, Pages: 148
“The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
The scope of this report includes:
- Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
- Analysis of the leading therapeutic segments including diabetes and obesity.
- Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
- Key M&A activities, licensing agreements that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis
The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges
Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
|
|
|
|
